论文部分内容阅读
美籍华人医药学家严海及其团队研发的胰高血糖素受体抗体药物,为1型糖尿病创造了新疗法,可替代每天注射胰岛素,避免其负面效果。2015年4月10日,“2014年度中关村十大系列榜单”发布,来自北京科信美德生物医药科技有限公司(以下简称“科信美德”)的创新成果“基于G蛋白偶联受体抗体药物共性技术平台开发的治疗Ⅰ型糖尿病的胰高血糖素受体抗体药物”荣获“2014中关村十大创新成
American Chinese medical scientist Yan Hai and his team developed glucagon receptor antibody drugs that create new therapies for type 1 diabetes, replacing daily injections of insulin and avoiding its negative effects. April 10, 2015, ”2014 Zhongguancun Top Ten Series List“ was released and the innovation results from Beijing Kexin Meide Biomedical Science and Technology Co., Ltd. (”Kexin Meide“) are based on G protein Coupled receptor antibody drug generic technology platform developed for the treatment of type 1 diabetes glucagon receptor antibody drug ”won" 2014 Zhongguancun Top Ten Innovative